Immunologic Biomarkers in Peripheral Blood of Persons With Tuberculosis and Advanced HIV.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 04 03 2022
accepted: 18 05 2022
entrez: 27 6 2022
pubmed: 28 6 2022
medline: 29 6 2022
Statut: epublish

Résumé

Tuberculosis (TB) is a common opportunistic infection among people living with HIV. Diagnostic tests such as culture, Xpert-MTB-RIF, and ULTRA have low sensitivity in paucibacillary TB disease; a blood biomarker could improve TB diagnostic capabilities. We assessed soluble factors to identify biomarkers associated with TB among persons with advanced HIV. A case-control (1:1) study was conducted, with participants from Rio de Janeiro and Manaus, Brazil. People living with HIV presenting with CD4 count ≤100 cells/mm3 were eligible to participate. Cases had culture-confirmed TB (N=15) (positive for Median CD4 count and HIV-1 RNA load values were similar between groups at all timepoints. Persons with TB had lower body mass index (BMI) (median=19.6, Interquartile Range [IQR]=18.6-22.3) than controls (23.7; IQR: 21.8 = 25.5, p=0.004). TB coinfection was also associated with increased frequency of other comorbidities. The overall profile of plasma cytokines, chemokines and growth factors were distinct between the study groups at all timepoints. Plasma concentrations of IL-15 and IL-10 were on average lower in TB cases than in controls. When used in combination, such markers were able to discriminate between TB cases and controls with the highest degree of accuracy at each study timepoint. Among persons with advanced HIV, plasma concentrations of IL-15 and IL-10 can be used in combination to identify TB disease regardless of time on anti-TB treatment.

Identifiants

pubmed: 35757685
doi: 10.3389/fimmu.2022.890003
pmc: PMC9226490
doi:

Substances chimiques

Biomarkers 0
Chemokines 0
Interleukin-15 0
Interleukin-10 130068-27-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

890003

Informations de copyright

Copyright © 2022 Queiroz, Araújo-Pereira, Barreto-Duarte, Gomes-Silva, Costa, Andrade, Miguez-Pinto, Spener-Gomes, Souza, Benjamin, Sant’Anna, Figueiredo, Mave, Salgame, Ellner, Sterling, Cordeiro-dos-Santos, Andrade and Rolla.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

BMC Infect Dis. 2018 May 15;18(1):220
pubmed: 29764370
Lancet. 2007 Jun 16;369(9578):2042-2049
pubmed: 17574096
Cochrane Database Syst Rev. 2019 Jun 07;6:CD009593
pubmed: 31173647
Int J Tuberc Lung Dis. 2008 Jul;12(7):769-72
pubmed: 18544202
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Lancet Microbe. 2021 Aug;2(8):e375-e385
pubmed: 34386782
Front Immunol. 2021 Feb 26;12:607827
pubmed: 33717089
Lancet Infect Dis. 2017 Dec;17(12):1285-1292
pubmed: 28847636
PLoS One. 2020 Oct 8;15(10):e0240090
pubmed: 33031403
Clin Infect Dis. 2019 Jul 2;69(2):295-305
pubmed: 30256919
J Epidemiol Community Health. 2009 Mar;63(3):233-8
pubmed: 19066188
Lancet Infect Dis. 2018 Jul;18(7):e199-e210
pubmed: 29580818
J Clin Microbiol. 2018 Nov 27;56(12):
pubmed: 30305387
Sci Rep. 2019 May 29;9(1):8002
pubmed: 31142816
Int J Epidemiol. 2010 Feb;39(1):149-55
pubmed: 19820104
Thorax. 2016 Sep;71(9):785-94
pubmed: 27146200
PLoS One. 2019 Feb 11;14(2):e0210856
pubmed: 30742626
PLoS Pathog. 2012 Feb;8(2):e1002464
pubmed: 22363214
Circulation. 2007 Feb 6;115(5):654-7
pubmed: 17283280
Int J Tuberc Lung Dis. 2004 Mar;8(3):286-98
pubmed: 15139466

Auteurs

Artur T L Queiroz (ATL)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil.

Mariana Araújo-Pereira (M)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil.
Curso de Medicina, Universidade Faculdade de Tecnologia e Ciências (UNIFTC), Salvador, Brazil.
Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil.

Beatriz Barreto-Duarte (B)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil.
Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil.
Programa de Pós-Graduação em Clínica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.

Adriano Gomes-Silva (A)

Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Laboratório Interdisciplinar de Pesquisas Médicas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Allyson G Costa (AG)

Instituto de Pesquisa Clínica Carlos Borborema, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil.

Alice M S Andrade (AMS)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil.
Curso de Medicina, Universidade Faculdade de Tecnologia e Ciências (UNIFTC), Salvador, Brazil.

João Pedro Miguez-Pinto (JP)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil.
Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil.

Renata Spener-Gomes (R)

Instituto de Pesquisa Clínica Carlos Borborema, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil.

Alexandra B Souza (AB)

Instituto de Pesquisa Clínica Carlos Borborema, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil.

Aline Benjamin (A)

Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Flavia Sant'Anna (F)

Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Marina C Figueiredo (MC)

Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.

Vidya Mave (V)

Byramjee-Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site (BJGMC-JHU CRS), Pune, India.
School of Medicine, Johns Hopkins University, Baltimore, MD, United States.

Padmini Salgame (P)

Rutgers- New Jersey Medical School, Center for Emerging Pathogens, Newark, NJ, United States.

Jerrold J Ellner (JJ)

Rutgers- New Jersey Medical School, Center for Emerging Pathogens, Newark, NJ, United States.

Timothy R Sterling (TR)

Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.

Marcelo Cordeiro-Dos-Santos (M)

Instituto de Pesquisa Clínica Carlos Borborema, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil.

Bruno B Andrade (BB)

Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research Initiative, Salvador, Brazil.
Curso de Medicina, Universidade Faculdade de Tecnologia e Ciências (UNIFTC), Salvador, Brazil.
Faculdade de Medicina, Universidade Federal da Bahia, Salvador, Brazil.
Curso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil.
Programa de Pós-Graduação em Clínica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, United States.
Curso de Medicina, Escola Bahiana de Medicina e Saúde Pública (EBMSP), Salvador, Brazil.

Valeria C Rolla (VC)

Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH